Skip to main content

Table 5 Prevalence of Pfmdr1 alleles and haplotypes in day 0 (pre-treatment) and day of recurrent infection samples in the artemether-lumefantrine arm, 2018–2019 therapeutic efficacy monitoring

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

aPfmdr1 codon Day 0 Day of recurrent infection
N86 128 (100%) 127 (100%)
86N/Y (N = 255) 0 (0%) 0 (0%)
86Y 0 (0%) 0 (0%)
Y184 48 (38%) 38 (32%)
Y184Y/F (N = 246) 37 (29%) 38 (32%)
184F 43 (34%) 42 (36%)
S1034 126 (100%) 111 (100%)
1034S/C (N = 237) 0 (0%) 0 (0%)
1034C 0 (0%) 0 (0%)
N1042 127 (100%) 111 (100%)
1042N/D (N = 238) 0 (0%) 0 (0%)
104D 0 (0%) 0 (0%)
D1246 116 (91%) 107(96%)
1246D/Y (N = 239) 5 (4%) 2(2%)
1246Y 6 (5%) 3 (3%)
Pfmdr1 haplotypesb n = 127c n = 110c
 NFD 78 (61%) 76 (69%)
 NYD 79 (62%) 68 (62%)
 YFD 0 0
 YYD 0 0
 YYY 0 0
 NYY 9 (7%) 4 (4%)
 YFY 0 0
 NFY 6 (5%) 3 (3%)
  1. aData presented are for participants with either later clinical failure or late parasitological failure
  2. bEach possible haplotype constructed from the mixed infections (wildtype and mutant) was reported. Haplotype percentages exceed a sum of 100% because all possible haplotypes from mixed infections (both wild type and mutants) were included in the construction of haplotypes
  3. cN includes samples for which data were available for all three markers